'Investor relations
After the squeeze-out procedure (that ran until 3 February 2012), Couckinvest holds/controls 99.26% of all shares outstanding. Payment of the shares tendered during the squeeze-out procedure is scheduled for 17 February 2012.
The remaining non-tendered shares are deemed transferred to Couckinvest NV by operation of law. These shareholders remain entitled to receive EUR 36 per share and should contact to that end the Belgian Deposit and Consignation Office where the corresponding funds will remain available for a period of thirty years.
Related press releases
Omega Pharma discloses the results of the squeeze-out procedure by Couckinvest (press release dd. 10 February 2012)
Omega Pharma's shareholder structure based on most recent notifications after reopening of the bid by Couckinvest (press release dd. 31 January 2012)
Omega Pharma discloses the results of the reopened takeover bid by Couckinvest (press release dd. 13 January 2012)
Omega Pharma's shareholder structure based on most recent notifications after the initial acceptance period of the takeover bid by Couckinvest (press release dd. 10 January 2012)
Omega Pharma discloses the results of the takeover bid by Couckinvest after the initial acceptance period (press release dd. 27 December 2011).
European Commission reports it has no objections against takeover of Omega Pharma by Couckinvest (press release dd. 15 December 2011)
Couckinvest launches a voluntary and conditional takeover bid on Omega Pharma against EUR 36 per share (press release dd. 2 September 2011)
Press release issued by Couckinvest NV on 22 September 2011
New composition executive committee and board of directors
Press release dd. 30 November 2011
Share buy-back programme
On 2 September 2011, the board of directors announced the activation of the share buy-back programme for which authorization was granted by the extraordinary shareholder meeting of 17 June 2011.
After every seven trading days, Omega Pharma publishes an interim status report:
- 12 September 2011
- 21 September 2011
- 30 September 2011
- 11 October 2011
- 20 October 2011
- 28 October 2011
As a result of the share buy-back programme, specific notification thresholds have been passed. See press release and transparency notifications.
News for shareholders
- The consolidated 2010 annual report is published in electronic format on this website, on 11 April. (Find here the Dutch-language statutory annual statements.
- The annual shareholder meeting took place on May 2, 2011. All motions have been approved. The presentation and the minutes (Dutch-language version) are available on this page. An English overview of the voting results is also available. The dividend over 2010 (gross €1.00 per share) became payable on 9 May 2011.
- On 17 June 2011, an extraordinary shareholder meeting took place. All motions were approved. Voting results
Most recent investor presentation (May 2011)
Contact for investor relations: Chris Van Raemdonck (chris.vanraemdonck@omega-pharma.be, +32/9/381.0331)
Annual information 2010: in accordance with the Law of 16 June 2006 on the public offer of placing instruments and the trading of placing instruments on regulated markets, the doucments referred to as 'annual information' in Title 10 of this law is included under the section "Press Releases" (archive 2010) of this website. Omega Pharma has not issued a prospectus in 2010. The company wishes to emphasize that the information in the documents referred to hereabove may have become outdated.
